NCT00262483View on ClinicalTrials.gov

Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2005

Study Completion Date

April 30, 2006

Conditions
Hepatitis C
Interventions
DRUG

VX-950

DRUG

ribavirin

DRUG

peginterferon alfa-2a

Trial Locations (2)

Unknown

Call for information, San Antonio

Call for information, Santurce

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT00262483 - Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C | Biotech Hunter | Biotech Hunter